- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | Regentis Biomaterials Ltd: Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology | 444 | ACCESS Newswire | Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need... ► Artikel lesen | |
| 15.07. | Regentis Biomaterials Ltd: Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch | 253 | ACCESS Newswire | European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial productionGelrinC... ► Artikel lesen | |
| 09.07. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.07. | REGENTIS BIOMATERIALS LTD. - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 02.07. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.06. | Regentis Biomaterials to raise $6.5M via private placement | 1 | Seeking Alpha | ||
| REGENTIS BIOMATERIALS Aktie jetzt für 0€ handeln | |||||
| 18.06. | Regentis Biomaterials Ltd: Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement | 712 | ACCESS Newswire | HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions... ► Artikel lesen | |
| 16.06. | Regentis Biomaterials Slips 9% After Soaring 506% On Monday - Here's Why RGNT Stock Is Trending | 5 | Benzinga.com | ||
| 15.06. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 09.06. | REGENTIS BIOMATERIALS LTD. - F-1/A, Registration statement for certain foreign private issuers | 5 | SEC Filings | ||
| 08.06. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.06. | Regentis Biomaterials Ltd: Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate | 556 | ACCESS Newswire | GelrinC, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European UnionRegentis is growing its network of European Centers of... ► Artikel lesen | |
| 28.05. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.05. | REGENTIS BIOMATERIALS LTD. - F-1, Registration statement for certain foreign private issuers | 3 | SEC Filings | ||
| 16.04. | Regentis Biomaterials Ltd: Regentis Implements Strategy for Commercial Deployment of GelrinC in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon | 797 | ACCESS Newswire | Collaboration with leading European orthopedic center in Italy supports GelrinC clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence... ► Artikel lesen | |
| 17.03. | Regentis Biomaterials Ltd: Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% | 439 | ACCESS Newswire | Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending... ► Artikel lesen | |
| 24.02. | REGENTIS BIOMATERIALS LTD. - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | ||
| 24.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update | 929 | ACCESS Newswire | $7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected... ► Artikel lesen | |
| 24.02. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CHINA PHARMA HOLDINGS | 8,640 | +0,23 % | China Pharma: Keine Erklärung für ungewöhnliche Handelsaktivitäten | ||
| BAYER | 47,000 | -1,30 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY | 2,840 | -0,35 % | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 43,190 | -0,02 % | Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? | ||
| AQUESTIVE THERAPEUTICS | 4,040 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| NOVO NORDISK | 43,100 | -0,74 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| MERCK KGAA | 134,25 | 0,00 % | Merck investiert in neues Prüfzentrum für Europa | DARMSTADT (dpa-AFX) - Der Pharma- und Technologiekonzern Merck KGaA hat an seinem Hauptsitz Darmstadt ein neues Prüfzentrum für die Freigabe von Arzneimitteln eröffnet. Die Investition beziffert das... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,68 | +0,50 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| LB PHARMACEUTICALS | 32,280 | -0,09 % | BMO initiates LB Pharmaceuticals stock at Outperform on drug data | ||
| JUPITER NEUROSCIENCES | 0,166 | -2,30 % | PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| TURN THERAPEUTICS | 10,180 | 0,00 % | Turn Therapeutics Inc. - 8-K, Current Report | ||
| GSK | 22,330 | +0,54 % | Novo Nordisk, Eli Lilly und GSK investieren Milliarden - warum Biotech plötzlich wieder zum Übernahmekandidaten wird | ||
| PFIZER | 21,855 | 0,00 % | BioNTech und Pfizer werden zum geopolitischen Pharmafall | Die gemeinsame Entwicklung des Corona-Impfstoffs galt als Musterbeispiel globaler Arbeitsteilung: deutsche mRNA-Forschung, amerikanische Pharmakapazitäten, internationale Produktion und staatlich organisierte... ► Artikel lesen | |
| VYNE THERAPEUTICS | 0,888 | -0,52 % | VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience | NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has approved a reverse stock split of VYNE's... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,340 | 0,00 % | Canaccord reiterates TriSalus stock Buy rating after KOL event |
Das Unternehmen REGENTIS BIOMATERIALS LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,035 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REGENTIS BIOMATERIALS LTD finden Sie auf Wallstreet Online.